Table 3. Demographic and clinicopathologic characteristics of different overall survival.
| Characteristics | Overall survival | P value | |||
|---|---|---|---|---|---|
| ≤5 years (n=5195) | % (89.69%) | >5 years (n=597) | % (10.31%) | ||
| Age | <0.001 | ||||
| <70 | 2,465 | 47.45% | 364 | 60.97% | |
| ≥70 | 2,730 | 52.55% | 233 | 39.03% | |
| Sex | <0.001 | ||||
| Female | 2,344 | 45.12% | 324 | 54.27% | |
| Male | 2,851 | 54.88% | 273 | 45.73% | |
| Race | 0.448 | ||||
| Black | 607 | 11.68% | 72 | 12.06% | |
| White | 4,150 | 79.88% | 466 | 78.06% | |
| Other | 438 | 8.43% | 59 | 9.88% | |
| Site | 0.291 | ||||
| Upper lobe | 3,358 | 64.64% | 403 | 67.50% | |
| Middle lobe | 248 | 4.77% | 30 | 5.03% | |
| Lower lobe | 1,589 | 30.59% | 164 | 27.47% | |
| Laterality | 0.153 | ||||
| Left | 2,148 | 41.35% | 265 | 44.39% | |
| Right | 3,047 | 58.65% | 332 | 55.61% | |
| Histology | <0.001 | ||||
| Squamous-cell carcinoma | 2,467 | 47.49% | 227 | 38.02% | |
| Adenocarcinoma | 2,728 | 52.51% | 370 | 61.98% | |
| Grade | 0.038 | ||||
| Grade I; Well differentiated | 364 | 7.01% | 56 | 9.38% | |
| Grade II; Moderately differentiated | 1,980 | 38.11% | 245 | 41.04% | |
| Grade III; Poorly differentiated | 2,806 | 54.01% | 290 | 48.58% | |
| Grade IV; Undifferentiated; anaplastic | 45 | 0.87% | 6 | 1.01% | |
| Stage-T | <0.001 | ||||
| T1 | 657 | 12.65% | 111 | 18.59% | |
| T2 | 1,564 | 30.11% | 160 | 26.80% | |
| T3 | 1,380 | 26.56% | 140 | 23.45% | |
| T4 | 1,594 | 30.68% | 186 | 31.16% | |
| Stage-N | <0.001 | ||||
| N0 | 613 | 11.80% | 102 | 17.09% | |
| N1 | 579 | 11.15% | 84 | 14.07% | |
| N2 | 3,295 | 63.43% | 364 | 60.97% | |
| N3 | 708 | 13.63% | 47 | 7.87% | |
| Chemotherapy | <0.001 | ||||
| No/unknow | 3,110 | 59.87% | 212 | 35.51% | |
| Yes | 2,085 | 40.13% | 385 | 64.49% | |
| Radiotherapy | <0.001 | ||||
| No/unknow | 3,542 | 68.18% | 200 | 36.52% | |
| Yes | 1,653 | 31.82% | 379 | 63.48% | |
| Surgery | <0.001 | ||||
| Yes | 1,527 | 29.39% | 371 | 62.14% | |
| No | 3,668 | 70.61% | 226 | 37.86% | |